Sarah Diepstraten

Sarah Diepstraten

Senior Research Officer, Blood Cells and Blood Cancer Division, Walter and Eliza Hall Institute
Sarah Diepstraten completed her PhD at La Trobe University in molecular genetics and developmental biology. She is now a post-doctoral scientist at the Walter and Eliza Hall Institute. Her research focuses on understanding how blood cancers become resistant to therapy and how this can be overcome. She develops genetic engineering approaches (CRISPR) to find genes involved in drug resistance. She has also taught in undergraduate science courses at La Trobe University and Melbourne University, and is passionate about science education.

More from this expert

The anti-cancer drug abemaciclib (also known as Vernezio) has this month been added to the Australian Pharmaceutical Benefits Scheme (PBS) to treat certain types of breast cancer.

Clinical Articles iconClinical Articles

Upcoming Healthed Webcast

Tuesday 30th September, 7pm - 9pm AEST

Speaker

A/Prof Spiros Fourlanos & Samantha Stuk

Director of Clinical Studies, Ballarat Clinical School at Deakin University

We invite you to our next free webcast, where A/Prof Spiros Fourlanos & Samantha Stuk discuss GLP-1RAs. Earn up to 4 hours CPD. Accredited with RACGP and ACRRM.